Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
Express Scripts
AstraZeneca
McKinsey
Mallinckrodt
Merck

Last Updated: January 25, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Cixutumumab

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug Cixutumumab?

Cixutumumab is an investigational drug.

There have been 32 clinical trials for Cixutumumab. The most recent clinical trial was a Phase 2 trial, which was initiated on February 1st 2009.

The most common disease conditions in clinical trials are Carcinoma, Lung Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are National Cancer Institute (NCI), Eli Lilly and Company, and ImClone LLC.

Recent Clinical Trials for Cixutumumab
TitleSponsorPhase
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory SarcomaNational Cancer Institute (NCI)Phase 2
18F FLT Imaging Studies of Treatment Response for Lung Cancer and ThymomaNational Cancer Institute (NCI)Phase 2
BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung CancerEli Lilly and CompanyPhase 2

See all Cixutumumab clinical trials

Clinical Trial Summary for Cixutumumab

Top disease conditions for Cixutumumab
Top clinical trial sponsors for Cixutumumab

See all Cixutumumab clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Harvard Business School
Johnson and Johnson
Medtronic
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.